The potential for molecular biomarkers to tip the balance from benefit to harm in lung cancer screening and nodule diagnosis and to enhance risk prediction warrants a robust discussion about how we determine their accuracy and readiness for clinical use.
Based on our experience at Cleveland Clinic, we favor centralized management of screening decisions in our health system, detailed and thorough shared decision-making visits with one-year follow up and concrete plans for managing incidental findings.
Primary care physicians play a vital role in detecting cancers at earlier stages. Lung cancer has the highest mortality rate of any cancer in the U.S., and screening can be controversial.
A new document advises physicians on using SBRT for high-risk scenarios involving tumor size and location and previous treatments for lung cancer in medically inoperable patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Vamsidhar Velcheti, MD, and his team are pursuing novel, targeted therapies for patients with a rare form of NSCLC.
The low-dose chest CT scan used for lung cancer screening frequently demonstrates incidental findings in the anatomic structures imaged from the neck to the upper abdomen. This study describes the frequency of incidental findings and their clinical and financial downstream effects.
Ground-breaking research shows combining radiology, especially stereotactic radiosurgery, and targeted drugs significantly increases survival in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
Patients with choroidal metastases can see flashing lights, floating spots and have distortion of their vision. A careful history and physical examination can uncover signs and symptoms of hidden cancer.
Dr. Jordan Reynolds, anatomic and molecular pathologist, discusses a case that illustrates how to diagnose lung cancer on small specimens.
A centralized counseling and shared decision-making visit prior to lung cancer screening can help patients make value-based decisions about their care and ensure a lung cancer screening program is high quality and patient centered.